As Calls For Patent Sharing To Fight Pandemic Intensify, Manufacturing May Be Bigger Issue
Scientists and lawyers ask companies to temporarily license their IP for free, as others advocate compulsory licenses; real issue may be the ability to make a COVID-19 treatment or vaccine widely available.
You may also be interested in...
Favorable Drug Pricing Language In COVID-19 Government Contracts May Backfire for Industry
Pharma has won pricing battles during the pandemic, but doesn’t seem to be winning war as senators on both sides of the aisle question how some drug companies were able to skirt controversial intellectual property ownership issues in COVID-19 drug and vaccine agreements with the US government. IP experts say the biggest harm to the government from the contracting language may not be the pricing concerns but the government’s ability to share leanings from the partnerships with other coronavirus development programs.
A Downside Of Pandemic Preparedness: Wall Street May Not Value Government Contracts
Human Genome Sciences founder William Haseltine says company's stock did not move following BARDA contract for its anthrax treatment; advises industry to forget about IP for COVID-19 products.
NIH Partnership To Pick COVID-19 Therapeutics For Clinical Trials; Results Anticipated By Summer
NIH public-private partnership with FDA, CDC, BARDA and 16 biopharma companies to rank most promising therapeutics and vaccines to advance into clinical trials; candidates expected to be tested simultaneously under master protocol.